Felicia Cosman - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Felicia Cosman

Showing results (61-70 of 117) with videos related to

Pageof 12

Sort By:

Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 25, 2026

Clinical impact of acute symptomatic vertebral fractures in the United States: A patient survey and chart reviewSteven W Ing, Michele McDermott, Eric Yeh, et al.

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 11, 2025

Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatideFelicia Cosman, Bruce H Mitlak, Yamei Wang, et al.

The Journal of Clinical Endocrinology and Metabolism|July 9, 2009

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agentFelicia Cosman, Robert A Wermers, Christopher Recknor, et al.

Menopause (New York, N.Y.)|February 21, 2018

Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosisMichael R McClung, Nicholas C Harvey, Lorraine A Fitzpatrick, et al.

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 3, 2013

Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifeneFelicia Cosman, Tony M Keaveny, David Kopperdahl, et al.

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 26, 2012

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT)Richard M Jacques, Steven Boonen, Felicia Cosman, et al.

American Journal of Obstetrics and Gynecology|July 16, 2003

Short-term urogenital effects of raloxifene, tamoxifen, and estrogenMichael D Vardy, Robert Lindsay, Richard J Scotti, et al.

Menopause (New York, N.Y.)|July 16, 2020

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtendSusan L Greenspan, Lorraine A Fitzpatrick, Bruce Mitlak, et al.

Current Medical Research and Opinion|September 24, 2020

Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosisPaul D Miller, John P Bilezikian, Lorraine A Fitzpatrick, et al.

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 19, 2006

Effects of cyclic versus daily hPTH(1-34) regimens on bone strength in association with BMD, biochemical markers, and bone structure in miceAkiko Iida-Klein, Christine Hughes, Shi Shou Lu, et al.

Pageof 12

Search research articles

Showing results (61-70 of 117) with videos related to

Sort By:

Pageof 12

Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 25, 2026

Clinical impact of acute symptomatic vertebral fractures in the United States: A patient survey and chart reviewSteven W Ing, Michele McDermott, Eric Yeh, et al.

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 11, 2025

Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatideFelicia Cosman, Bruce H Mitlak, Yamei Wang, et al.

The Journal of Clinical Endocrinology and Metabolism|July 9, 2009

Menopause (New York, N.Y.)|February 21, 2018

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 3, 2013

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 26, 2012

American Journal of Obstetrics and Gynecology|July 16, 2003

Short-term urogenital effects of raloxifene, tamoxifen, and estrogenMichael D Vardy, Robert Lindsay, Richard J Scotti, et al.

Menopause (New York, N.Y.)|July 16, 2020

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtendSusan L Greenspan, Lorraine A Fitzpatrick, Bruce Mitlak, et al.

Current Medical Research and Opinion|September 24, 2020

Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosisPaul D Miller, John P Bilezikian, Lorraine A Fitzpatrick, et al.

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 19, 2006

Effects of cyclic versus daily hPTH(1-34) regimens on bone strength in association with BMD, biochemical markers, and bone structure in miceAkiko Iida-Klein, Christine Hughes, Shi Shou Lu, et al.

Pageof 12